Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802543 | 1.00 | HRH3 (0.47) | HRH3LTA4HCHRM4MEN1KMT2A | |
| SCHEMBL6095321 | 1.00 | HRH3 (0.47) | HRH3LTA4HCHRM4MEN1KMT2A | |
| SCHEMBL5805939 | 0.87 | HRH3 (0.45) | HRH3LTA4HMEN1KMT2AACHE | |
| SCHEMBL5805940 | 0.87 | HRH3 (0.45) | HRH3LTA4HMEN1KMT2AACHE | |
| SCHEMBL5805936 | 0.87 | HRH3 (0.45) | HRH3LTA4HMEN1KMT2AACHE | |
| SCHEMBL5805344 | 0.84 | HRH3 (0.50) | HRH3MEN1KMT2AACHEALDH1A1 | |
| SCHEMBL5805347 | 0.84 | HRH3 (0.50) | HRH3MEN1KMT2AACHEALDH1A1 | |
| SCHEMBL5787700 | 0.84 | HRH3 (0.60) | HRH3MEN1KMT2AALDH1A1 | |
| SCHEMBL5787699 | 0.84 | HRH3 (0.60) | HRH3MEN1KMT2AALDH1A1 | |
| SCHEMBL5787231 | 0.81 | HRH3 (0.61) | HRH3LTA4HALDH1A1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720847-A1 | HISTAMINE-3 RECEPTOR MODULATORS | Pfizer Products Incorporated (US) | 2006-11-15 | — | — | EP | claimed |
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | claimed |
| WO-2005080361-A1 | HISTAMINE-3 RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | claimed |
| EP-1720847-A1 | HISTAMINE-3 RECEPTOR MODULATORS | Pfizer Products Incorporated (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2005080361-A1 | HISTAMINE-3 RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | HRH3, HRH4, HRH1 | HRH3 1/4885LTA4H 329/4885CHRM4 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.